Ken Griffin Adagene Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$1.96 - $4.15 $25,470 - $53,929
12,995 New
12,995 $36,000
Q1 2023

May 15, 2023
BUY
$1.27 - $1.95 $16,262 - $24,969
12,805 New
12,805 $18,000
Q1 2022

May 16, 2022
SELL
$3.5 - $8.79 $58,635 - $147,258
-16,753 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$7.4 - $14.44 $41,573 - $81,123
-5,618 Reduced 25.11%
16,753 $135,000
Q1 2021

May 17, 2021
BUY
$17.0 - $29.99 $380,307 - $670,906
22,371 New
22,371 $402,000

Others Institutions Holding ADAG

# of Institutions
13
Shares Held
9.87M
Call Options Held
0
Put Options Held
0
View Full List

About Adagene Inc.

ADAG Quotes by TradingView
  • Ticker ADAG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,423,200
  • Market Cap $86.4M
  • Description
  • Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...
More about ADAG
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email